SynCardia Temporary Total Artificial Heart as Bridge to Transplantation: Current Results at La Pitié Hospital

Kirsch, Matthias; Nguyen, Albert; Mastroianni, Ciro; Pozzi, Matteo; Léger, Philippe; Nicolescu, M; Varnous, Shaïda; Pavie, Alain; Leprince, Pascal

doi:10.1016/j.athoracsur.2013.02.036

Cited by 48 publications

(47 citation statements)

References 21 publications

(30 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The successful surgical intervention and prompt management and prevention of postoperative complications were considered important factors in improving the outcome of heart transplantation in patients supported for the long term with a TAH. 72% of the patients with a SynCardia TAH underwent successful cardiac transplantation in the study by Torregrossa et al This outcome was confirmed by other studies as well; the study by Copeland et al reported 86% survival rates and a French study reported that the actual estimate of survival under TAH support was found constant between 120 and 360 days [13,14]. It can be secondary to long-term adequate systemic flow provided by TAH to fulfill all the metabolic and physiological demands, pointing towards its suitability as a completely implantable TAH, although more trials are needed to support this notion.…”

Section: Discussionsupporting

confidence: 78%

Total Artificial Heart as the Destination Therapy: A Review

Minhas¹

2017

AJCTS

View full text Add to dashboard Cite

Introduction: For the patients awaiting cardiac transplantation, mechanical circulatory support has been widely utilized in the form of left ventricular assist device or total artificial heart. Both total artificial heart and left ventricular assist device have been approved for the use as a bridge to transplantation therapy; however only left ventricular assist device has been approved for use as the destination therapy. The purpose of this review is to establish, using this literature, the possibility for the artificial heart transplant to be used as destination therapy besides highlighting the recent developments in this area of research in order to narrate the future of artificial heart transplantation.

show abstract

Section: Discussionsupporting

confidence: 78%

Total Artificial Heart as the Destination Therapy: A Review

Minhas¹

2017

AJCTS

View full text Add to dashboard Cite

show abstract

“…[10][11][12] Those results are mainly owing to rigorous patient selection and decision to proceed to temporary circulatory support, although these patients were at high risk of immediate death. Kirsch and colleagues 15 identified older age and preoperative mechanical ventilation as major risk factors while on support. Others have also reported preoperative mechanical ventilation as a risk factor for death while on support.…”

Section: Survival After Transplantationmentioning

confidence: 99%

“…This incidence of neurologic events was similar to those reported around the world. [11][12][13][14][15] However, most of these studies are retrospective by nature and could have underestimated the incidence of stroke, because not all patients underwent systematic brain imaging. In the present study, we performed brain imaging on a clinical basis only.…”

Section: Survival After Transplantationmentioning

confidence: 99%

“…5 La Pitié-Salpêtrière Hospital reported a similar success rate of BTT of 61% after a mean support duration of 97 ± 97 days. 15 At our institution, the TAH is the preferred device for durable biventricular support in eligible patients awaiting transplantation. The BTT rate compares favourably with those reported in the literature.…”

Section: Survival After Transplantationmentioning

confidence: 99%

See 1 more Smart Citation

Experience with the SynCardia total artificial heart in a Canadian centre

Nguyen

Pellerin

Perrault

et al. 2017

CJS

Self Cite

View full text Add to dashboard Cite

Background:The SynCardia total artificial heart (TAH) provides complete circulatory support by replacing both native ventricles. Accepted indications include bridge to transplantation and destination therapy. We review our experience with TAH implantation during a period when axial flow pump became available. Methods:We retrospectively analyzed the demographics, clinical characteristics and survival of all patients receiving the TAH. Results:From September 2004 to November 2016, 13 patients (12 men, mean age 45 ± 13 yr) received the TAH for refractory cardiogenic shock secondary to idiopathic (56%) or ischemic (17%) cardiomyopathy and to other various causes (33%). Before implantation, mean ejection fraction was 14% ± 4%, 7 (54%) patients had previous cardiac surgery, 4 (31%) were on mechanical ventilation, and 3 (23%) patients were on dialysis. The mean duration of TAH support was 46 ± 40 days. Three (23%) patients died while on support after a mean of 15 days. Actuarial survival on support was 77% ± 12% at 30 days after implantation. Complications on support included stroke (n = 1, 8%), acute respiratory distress syndrome requiring prolonged intubation (n = 5, 38%) and acute renal failure requiring temporary dialysis (n = 5, 38%). Ten (77%) patients survived to be transplanted after a mean of 52 ± 42 days of support. Actuarial survival rates after transplant were 67% ± 16% at 1 month and 56% ± 17% at 1 year after transplantation. Conclusion:The TAH provides an alternative with low incidence of neurologic events in extremely fragile and complex patients waiting for heart transplantation. Complex and unusual anatomic conditions explained the current use of TAH.

show abstract

“…Examples include the outcomes of patients implanted with a total artificial heart (TAH) or with short-term mechanical circulatory support devices (12,13). The small numbers of implants relative to other devices and therapies make any meaningful data analysis regarding waiting list mortality and posttransplant survival very limited.…”

Section: Limitations Of the Proposed Modified Systemmentioning

confidence: 99%